Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.

Journal of Experimental & Clinical Cancer Research : CR
Eiji ToyodaShinji Uemoto

Abstract

To develop a novel therapeutic strategy for human pancreatic cancer using a midkine promoter-based conditionally replicating adenovirus. We examined midkine mRNA expression and midkine protein expression by seven human pancreatic cancer cell lines (AsPC-1, BxPC-3, CFPAC-1, HPAC, MIAPaCa-2, PANC-1, and Suit-2), as well as by non-cancerous pancreatic tissue and pancreatic cancers. Midkine promoter activity was measured in cancer cell lines by the dual luciferase reporter assay. Adenoviral transduction efficiency was assessed by fluorescent staining of cancer cell lines using adenovirus type 5 containing the green fluorescent protein gene (Ad5GFP). Replication of adenovirus type 5 containing the 0.6 kb midkne promoter (Ad5MK) was assessed by the detection of E1 protein in cancer cell lines. The cytotoxicity of Ad5MK for cancer cells was evaluated from the extent of growth inhibition after viral infection. Infection and replication were also assessed in nude mice with subcutaneous Suit-2 tumors by intratumoral injection of Ad5MK, Ad5GFP, or vehicle. E1a mRNA expression in the treated tumors and expression of the replication-specific adenoviral hexon protein were evaluated. Finally, the anti-tumor activity of Ad5MK against intraperi...Continue Reading

References

Apr 30, 1991·Biochemical and Biophysical Research Communications·J TsutsuiT Muramatsu
Nov 13, 1995·Biochemical and Biophysical Research Communications·S KojimaT Muramatsu
Jul 1, 1995·Japanese Journal of Cancer Research : Gann·K AridomeT Muramatsu
Jan 1, 1997·British Journal of Cancer·K KadomatsuT Muramatsu
Oct 23, 2001·International Journal of Cancer. Journal International Du Cancer·D M ParkinP Pisani
Dec 26, 2001·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F BrayD M Parkin
Apr 18, 2002·Cancer Gene Therapy·Andrew V HubbersteyRobin J Parks
Mar 20, 2003·Cancer Investigation·B F el-RayesP A Philip
Jul 3, 2004·Japanese Journal of Clinical Oncology·Albert B Lowenfels, Patrick Maisonneuve
Jul 15, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L YuM Tagawa

❮ Previous
Next ❯

Citations

Apr 19, 2015·Journal of Experimental & Clinical Cancer Research : CR·Steven J ConradKarim Essani
Jun 24, 2015·European Journal of Pharmacology·Elisabeta BădilăAdriana Georgescu
Jan 1, 2010·Cancers·Hirofumi Jono, Yukio Ando
Jan 1, 2011·Cancers·Cristina FillatLuciano Sobrevals
Dec 6, 2019·Oncogene·Panagiota S FilippouAnastasia Constantinidou
Jan 13, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Helga L WeberOsvaldo L Podhajcer

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection
pancreatectomy
PCR
protein assay
X-ray
xenograft
fluorescence microscopy
xenografts
transfection

Software Mentioned

JMP

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.